Janssen HLA - Search Results

1

Long-term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.

Chan HLY, Buti M, Lim YS, Agarwal K, Marcellin P, Brunetto M, Chuang WL, Janssen HLA, Fung S, Izumi N, Abdurakhmanov D, Jabłkowski M, Celen MK, Ma X, Caruntu F, Flaherty JF, Abramov F, Wang H, Camus G, Osinusi A, Pan CQ, Shalimar D, Seto WK, Gane E. Chan HLY, et al. Among authors: janssen hla. Am J Gastroenterol. 2023 Aug 10;119(3):486-96. doi: 10.14309/ajg.0000000000002468. Online ahead of print. Am J Gastroenterol. 2023. PMID: 37561058 Free PMC article.

2

Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP).

Janssen HL, Gerken G, Carreño V, Marcellin P, Naoumov NV, Craxi A, Ring-Larsen H, Kitis G, van Hattum J, de Vries RA, Michielsen PP, ten Kate FJ, Hop WC, Heijtink RA, Honkoop P, Schalm SW. Janssen HL, et al. Hepatology. 1999 Jul;30(1):238-43. doi: 10.1002/hep.510300113. Hepatology. 1999. PMID: 10385662 Clinical Trial.

3

Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.

Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL; HBV 99-01 Study Group. Flink HJ, et al. Am J Gastroenterol. 2006 Feb;101(2):297-303. doi: 10.1111/j.1572-0241.2006.00418.x. Am J Gastroenterol. 2006. PMID: 16454834 Clinical Trial.

4

Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine.

Flink HJ, Hansen BE, Heathcote EJ, Feinman SV, Simsek H, Karayalcin S, Mach T, Leemans WF, de Man RA, Verhey E, Schalm SW, Janssen HL; HBV 99-01 Study Group. Flink HJ, et al. Am J Gastroenterol. 2006 Nov;101(11):2523-9. doi: 10.1111/j.1572-0241.2006.00812.x. Epub 2006 Oct 4. Am J Gastroenterol. 2006. PMID: 17029610 Clinical Trial.

5

Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis.

Buster EH, Hansen BE, Buti M, Delwaide J, Niederau C, Michielsen PP, Flisiak R, Zondervan PE, Schalm SW, Janssen HL; HBV 99-01 Study Group. Buster EH, et al. Hepatology. 2007 Aug;46(2):388-94. doi: 10.1002/hep.21723. Hepatology. 2007. PMID: 17604363 Clinical Trial.

6

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.

Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL. Buster EH, et al. Gastroenterology. 2008 Aug;135(2):459-67. doi: 10.1053/j.gastro.2008.05.031. Epub 2008 May 15. Gastroenterology. 2008. PMID: 18585385 Clinical Trial.

7

Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.

Leemans WF, Niesters HG, van der Eijk AA, Janssen HL, Schalm SW, de Man RA. Leemans WF, et al. Eur J Gastroenterol Hepatol. 2008 Aug;20(8):773-7. doi: 10.1097/MEG.0b013e3282f793d6. Eur J Gastroenterol Hepatol. 2008. PMID: 18617782

8

Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.

Buster EH, Schalm SW, Janssen HL. Buster EH, et al. Best Pract Res Clin Gastroenterol. 2008;22(6):1093-108. doi: 10.1016/j.bpg.2008.11.007. Best Pract Res Clin Gastroenterol. 2008. PMID: 19187869 Review.

9

Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients.

Buster EH, Flink HJ, Simsek H, Heathcote EJ, Sharmila S, Kitis GE, Gerken G, Buti M, de Vries RA, Verhey E, Hansen BE, Janssen HL. Buster EH, et al. Am J Gastroenterol. 2009 Oct;104(10):2449-57. doi: 10.1038/ajg.2009.371. Epub 2009 Jul 7. Am J Gastroenterol. 2009. PMID: 19584831 Clinical Trial.

10

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.

Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL. Buster EH, et al. Gastroenterology. 2009 Dec;137(6):2002-9. doi: 10.1053/j.gastro.2009.08.061. Epub 2009 Sep 6. Gastroenterology. 2009. PMID: 19737568

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

554 results

Search Page